A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Public ClinicalTrials.gov record NCT06646276. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Study identification
- NCT ID
- NCT06646276
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 530 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Biological
- BMS-986489 (BMS-986012+Nivolumab) Biological
- Carboplatin Drug
- Etoposide Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 24, 2025
- Primary completion
- Apr 5, 2028
- Completion
- Sep 4, 2031
- Last update posted
- Apr 20, 2026
2025 – 2031
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, PC | Daphne | Alabama | 36526 | Recruiting |
| Local Institution - 0283 | Hot Springs | Arkansas | 71913 | Completed |
| Florida Cancer Specialists - South | Fort Myers | Florida | 33901 | Recruiting |
| Mid Florida Hematology and Oncology Center | Orange City | Florida | 32763 | Recruiting |
| Florida Cancer Specialists - North | St. Petersburg | Florida | 33705 | Recruiting |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Marietta | Georgia | 30060 | Recruiting |
| Illinois Cancer Care | Peoria | Illinois | 61615 | Recruiting |
| Local Institution - 0037 | Minneapolis | Minnesota | 55407 | Withdrawn |
| University of New Mexico Comprehensive Cancer Center | Albuquerque | New Mexico | 87106 | Recruiting |
| Duke Cancer Institute | Durham | North Carolina | 27710 | Recruiting |
| Sanford Medical Center | Bismarck | North Dakota | 58501 | Recruiting |
| Local Institution - 0010 | Fargo | North Dakota | 58102 | Not yet recruiting |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | Recruiting |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57104 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - Central/South Texas | Austin | Texas | 78705 | Recruiting |
| Texas Oncology - Northeast Texas | Tyler | Texas | 75702 | Recruiting |
| Oncology & Hematology Associates of Southwest Virginia, Inc. | Roanoke | Virginia | 24014 | Recruiting |
| Swedish Cancer Institute - Edmonds | Edmonds | Washington | 98026 | Recruiting |
| Swedish Medical Center | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 164 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06646276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06646276 live on ClinicalTrials.gov.